SHShahrukh Hashmi

Shahrukh Hashmi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shahrukh Hashmi has a total of 62 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Decentralized CAR-T production: clinical, economic, and regulatory perspectives. Worldwide Network for Blood & Marrow Transplantation (WBMT) special article

    by Abdulrahman Nasiri, Riad El Fakih, Christian Chabannon, Laurent Garderet, Jurgen Kuball, Ali Bazarbachi, Anna Sureda, Marcos De Lima, Muhammad Bilal Abid, Farhatullah Syed, et al.

    Chimeric antigen receptor T-cell therapy transformed the treatment of hematologic malignancies and is rapidly expanding into solid tumors and autoimmune diseases. However, its full clinical potential remains constrained by centralized manufacturing, production costs, logistical complexity, prolonged vein-to-vein times, limited global accessibility, and regulatory frameworks that hinder rapid implementation of manufacturing innovations. Decentralized point-of-care manufacturing, pioneered by academic and clinical centers, offers a promising alternative to address these limitations and broaden patient access. This review summarizes the current landscape of POC CAR T-cell manufacturing, emphasizing clinical outcomes, economic sustainability, and regulatory considerations. Program experience across North America, Europe, Asia, and other regions demonstrates manufacturing innovations that reduce production times from several weeks to as few as 6–8 days. Early clinical studies report safety and efficacy comparable to commercially manufactured products while substantially lowering costs, with some models targeting production expenses of approximately USD 40,000 per treatment (excluding building and maintaining the production facility). We also examine supportive policy initiatives and regulatory pathways, including hospital exemption models, together with implementation challenges such as manufacturing heterogeneity, quality assurance, and workforce development. Finally, we discuss emerging technologies, including allogeneic CAR T-cell platforms, artificial intelligence-driven manufacturing, and in vivo gene editing, that may democratize global access.


  • The promise of adaptive health in the United Arab Emirates and beyond

    by Andrew P. Feinberg, Eduardo Beltrame, Mohamed Alameri, Eran Segal, Shahrukh Hashmi, David Threadgill

  • Futuristic global cell and gene therapy regulations based on a review of today’s leading frameworks

    by Shahrukh K. Hashmi, M. Abdullah Jamil, Josu de la Fuente, Johnny Mahlangu, Margareth C. Ozelo, Mark C. Walters, Asma Almannaei, Alok Srivastava, Hazza Alzahrani, Peihua Lu, et al.


  • Open Access

    Elevated Graft-versus-Host Disease Risk Among International Stem Cell Transplant Recipients: A Pilot Study from the UAE

    by Syed Naveed, Afrooz Imrana, Mir Ahmed Farooq, Khan Ali Azmat, Abdulla J.M.H Nada, Hussain Shakir, Chandani Uttam Ashok, Hasan Amera, Samad Abdel Hanin, ElGhazali Gehad, et al.

    Patients from regions without stem cell transplant (SCT) facilities often seek treatment abroad and return home for post-transplant care. While extensive data exists on GVHD and its risk factors, the prevalence of GVHD in international SCT patients returning to countries without transplant facilities, where multiple factors compromise post-transplant care, is not well documented. We screened 149 transplant recipients and analyzed data from 91 who received transplants abroad and were followed at our center from January 2019 to December 2022. This observational study used data from electronic medical records (EMR) and employed descriptive statistics, inferential tests, and relative risk calculations with forest plots to analyze GVHD prevalence and key risk factors. Of the recipients, 31.8% were residents from nine countries living in the UAE, and 67.2% were UAE citizens. Adults comprised 48.3% of the recipients, and 51.7% were pediatric. Hematological malignancies were the most common indication (49%), primarily in adults. Siblings were the majority of donors (52.6%), followed by related donors (23.09%), and unrelated donors (8.9%). Most (69.2%) received HLA-identical transplants followed by 21.9% who received haploidentical. Among adults, 62.2% developed GVHD, compared to 26% of pediatric patients. Recipients with related HLA-identical donors had a 50% GVHD prevalence, while those with unrelated identical donors had 71%. The overall GVHD prevalence was 50% among the 87.9% who received allogeneic SCTs. Despite favorable factors, GVHD prevalence remains high. Larger multicenter studies are needed to identify and assess the impact of contributing factors.